12015.8.9. 27 1 PPA

M5

undifferentiatedALL

stem cell

CFU-GEMM

CFU-GM

BFU-E

CFU-Meg

pre-pre-B pre-B immature B mature B

pre-T early-T

M0

M4

CNL M2 M3M1

M6

M7

Common ALL

common-T

preT-ALL T-ALL

BB

LymphomaLymphoma

MyelomaMyeloma

CMLCMLMDSMDS

Leukemia(ALL)Leukemia(ALL)

Leukemia(AML)Leukemia(AML)

CLLCLL

FAB 1982 1994

Revised Rappaport’s/WHO/Lukes-Collins/Kiel 1976

Working Formulation (WF) 1982~1988

REAL 1994

WHO Jaffe ES et al 2001

/

2008 10Ver.4

VIII®

FS®

®IX®

®

DNA,RNA

<1> DNADNA

6-

2) DNA

<2> .

SIADH

<3> L-

L-

( 40%)WBC MPO

t(8;21), inv(16),t(15;17) ( 70%)t(15;17) M3

: ( A )® ®

( 40 50%)FLT3-ITD NPM1

JALSG ALL93 33%

•Clonal evolu�on

Ph

• de novo

••

(5-Year 93%)

IFN or SCT 2nd line (5-Year 71%)

IFN or SCT (5-Year 63%)

IFN (5-Year 53%)

(5-Year 38%)

16

IFN:SCT

Type 1 Type 2

T315I

TKI

ABL

TKI

3rd TKI Abl, SrcT315I V299L

2nd TKIImatinib ABL

NEJM 354 2542-2551, 2006

Src screeningATP

ImatinibImatinib 325NEJM 354 2531-2541, 2006

Kumar SK. et al. Blood 2008; 111: 2516-2520

M 3g/dl10

No Yes

And

• 1960••

–

• 2008 10– TERMS

• Immunomodulatory drugs (IMiDs)•

–

–• 2010 7

– RevMate

4

• 26S• I B NF- B•

–• 2006 10

Immunomodulatory drugs (IMiDs)••

–

– 2015 3

CD20 )C5

CCR4

IL6CD33

CD30

CD20

CD30 internalization

CD33

calicheamicin

CD33

CD30

CD20

MMAE

ALCL

.

2001 9Pathol Int 2000;50:696-702.

Coiffier B et al. N Engl J Med 2002;346:235-24210 Blood 2010; 116:2040-2045

anti-CD20 McAb - 90Y Ibritumomab Tiuxetan

(Zevalin ) 2008

43.5%

24.6%

PNH

Flower Cells

.

CCR4

AZT 19771985 1990

2015 ~( )

19831986 1991

2010

R-CHOPDay 1 2 3 4 5 6

Rituximab 375 mg/m2 (div)

CY 750 mg/m2 (div)

DXR 50 mg/m2 (div)

VCR 1.4 mg/m2 (max 2mg) (iv)

PSL 100 mg/body (po)

PEG-G-CSF

2 5

PEG

Metcalf D., Nature 1994;364:519

Stem Cells 16: 322-328, 1998

~70kDa

332 (TPO exon intron3q27-28

Malignant mesothelioma

IL-6

(Plt=170 )

Higashihara M, et al: Cancer 70: 2105-2108, 1992

STAT PP

RAS/RAF

MAPKK

p42/44

SOSSOS

GRB2

P P

JAK

SHCTPO

TPO

PI3K

AKT

J. Cell Biol. 147:1299, 1999

WF

ITPStandardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group

---------------------------------------------------------------------------------------------Idiopathic (immune) Thrombocytopenic Purpura (ITP)

ImmunePurpura

Immune Thrombocytopenia (ITP)primarysecondary i.e. secondary ITP(lupus-associated)

lupus-associated ITP

Blood 2009;113: 2386

Kurata Y, et al. Int J Hematol 93:329, 2011

2004~2007 7,774

130

56

1. 22,853

2. 9,4793. 1,192

201253:433-42, 2012

ITP

NEJM 355:1672, 2006

mpl Fc

~60kD

Increased platelet destruction ( )Anti-platelet immunity

Anti-megakaryocyteimmunity

Decreased platelet production

( )

A•

Kumagai Y, et al. J Clin Pharmacol 2007;47(12):1489-97.

• Shirasugi Y, et al. Int J Hematol, 2009

• 3Miyazaki K, et al. (ASH, 2010; EHA, 2011 )Shirasugi Y, et al. Int J Hematol 2011; 2012

0.3, 1, 2μg/kg 1μg/kg

1μg/kg 4/8 1.5 2μg/kg 3/8 1.5 3/8 2TPO ( 2005 )

Romiplostim

2010 12 28

2011 1 21

2008

1~10μg/kgic

2010 12 10

200812.5~50mg/body

: 546

ITP

H.Pylori

First line

Second line

Third line

H.Pylor

i(+)

H.Pylori(-)

201253:433-42, 2012

2. Metronidazole 500mg 2x

2010 6 18 ITP3

H.Pylori

2005 69%(300/435)63%(103/163)

(

48